Work

Clinical models to predict response and survival in metastatic melanoma (MM) patients (pts) treated with anti-PD-1 alone (PD1) or combined with ipilimumab (IPI+PD1).

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.9542

Authors: Ines Esteves Domingues Pires Da Silva, Tasnia Ahmed, Serigne Lo, Rajat Rai, Jessica Louise Smith, John J. Park, Caroline Nabhan, Richard A. Scolyer, Matteo S. Carlino, Jennifer Leigh McQuade, Douglas Buckner Johnson, Georgina V. Long, Alexander M. Menzies

Institutions: Melanoma Institute Australia, The University of Sydney, Westmead Hospital, Vanderbilt University Medical Center, Royal Prince Alfred Hospital, The University of Texas MD Anderson Cancer Center, Royal North Shore Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2947050727

Cites:

Cited by: 2

Related to: 10